Meeting
2015 ASCO Annual Meeting
SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma.
Authors
Alain Patrick Algazi
University of California, San Francisco, San Francisco, CA
Alain Patrick Algazi , Megan Othus , Adil Daud , Janice M. Mehnert , Christopher D. Lao , Ragini Reiney Kudchadkar , Kenneth F. Grossmann , Roger Lo , James Moon , John M. Kirkwood , Antoni Ribas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT02196181
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS9093)
DOI
10.1200/jco.2015.33.15_suppl.tps9093
Abstract #
TPS9093
Poster Bd #
329a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
IMPemBra, a phase 2 study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation: Three-year survival data and translational analyses.
First Author: Elisa A. Rozeman
Poster
2020 ASCO Virtual Scientific Program
The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the BRAFV600 mutation.
First Author: Elisa A. Rozeman
Poster
2012 ASCO Annual Meeting
BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).
First Author: Ryan Bruce Corcoran
Poster
2023 ASCO Annual Meeting
Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.
First Author: Paul B. Chapman